Key result
Asymmetric dimethylarginine activity is strongly correlated with cardiovascular disease in prediabetes.
Why the study?
Is Asymmetric Dimethylarginine (ADMA) correlated with cardiovascular disease in patients with prediabetes?
Is Asymmetric Dimethylarginine (ADMA) correlated with cardiovascular disease in patients with prediabetes?
Asymmetric dimethylarginine (ADMA) is highlighted as a significant biomarker associated with endothelial dysfunction and cardiovascular disease risk in patients with prediabetes.
Supports ADMA as a potential CVD biomarker in prediabetes; leaves open its incremental value and causality.
Asymmetric dimethylarginine (ADMA) is now well established as a major risk factors for cardiovascular disease (CVD) impact upon endothelial function by decreasing nitric oxide (NO) bioavailability. Asymmetric dimethylarginine, an endogenous analog of l -arginine, is able to inhibit the activity of endothelial-nitric oxide synthase (eNOS), promoting endothelial dysfunction. Prediabetes is characterized by a reduced endotheliumdependent vasodilation and increased ADMA levels. Asymmetric dimethylarginine is strongly associated with micro-and macrovascular diabetic complications. Asymmetric dimethylarginine activity is strongly correlated with CVD in prediabetes.
No takes yet. Share an insight, caveat, or question.
Bidwe et al. (2018) conducted a review in Prediabetes and Cardiovascular Disease. Asymmetric dimethylarginine (ADMA) was evaluated on Cardiovascular disease. Asymmetric dimethylarginine activity is strongly correlated with cardiovascular disease in prediabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: